Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20213673 | 0.78 | MAPK1 (0.42) | HIF1APDCD1CD274PDE10A | |
| SCHEMBL20854982 | 0.77 | ALDH1A1 (0.47) | WDR5PDCD1CD274NPC1RAB9A | |
| SCHEMBL20854927 | 0.74 | NPC1 (0.46) | NPC1RAB9APDE10A | |
| SCHEMBL2523005 | 0.67 | THRB (0.42) | HIF1A | |
| SCHEMBL20575611 | 0.65 | TGFBR1 (0.55) | HIF1AWDR5NPC1RAB9APDE10A | |
| SCHEMBL10939995 | 0.64 | NPC1 (0.41) | NPC1RAB9A | |
| SCHEMBL10941820 | 0.64 | NPC1 (0.49) | NPC1RAB9APDE10A | |
| SCHEMBL2522496 | 0.63 | CSNK1D (0.47) | NPC1RAB9A | |
| SCHEMBL1083814 | 0.63 | HIF1A (0.97) | HIF1ARAB9A | |
| SCHEMBL1084817 | 0.63 | HIF1A (0.92) | HIF1ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-10975095-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | HIF1A 1677/4885WDR5 3655/4885PDCD1 3766/4885 |
| US-10975095-B2 | — | CYP1B1, UGT1A1, CYP4B1 | HIF1A 2801/4885WDR5 2168/4885PDCD1 4634/4885 |
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | HIF1A 2247/4885WDR5 376/4885PDCD1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.